The Effect of Fenoprofen Calcium (Nalfon) on Levels of Rheumatoid Factor in Patients with Rheumatoid Arthritis

1973 ◽  
Vol 1 (2) ◽  
pp. 412-416
Author(s):  
Joan E Himes ◽  
Ivan F Duff
Keyword(s):  
Rheumatoid Arthritis ◽  
Rheumatoid Factor ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
The Mean ◽  
Baseline Levels ◽  
One Year

In 88.9% of a group of 18 patients with rheumatoid arthritis participating in an open-label study with fenoprofen calcium (Nalfon), there was observed a mean litre decrease in level of rheumatoid factor as compared to baseline levels. In follow-up, three months to one year later, a uniform litre increase above the mean level of the study period had occurred. In all cases the titre returned to baseline levels or higher.

Riluzole in Huntington's disease (HD): an open label study with one year follow up

2001 ◽  
Vol 248 (10) ◽  
pp. 866-869 ◽  
Author(s):  
Klaus Seppi ◽  
Joerg Mueller ◽  
Thomas Bodner ◽  
Elisabeth Brandauer ◽  
Thomas Benke ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
One Year

scholarly journals BINOCULAR IMPLANTATION OF NEW DIFFRACTIVE TRIFOCAL INTRAOCULAR LENS FOR PRESBYOPIA CORRECTION

2018 ◽  
Vol 24 (5) ◽  
pp. 228-232
Author(s):  
K. B Pershin ◽  
N. F Pashinova ◽  
Alexander Iu. Tsygankov ◽  
O. P Miyovich ◽  
I. A Likh ◽  
...  
Keyword(s):  
Intraocular Lens ◽  
Functional Results ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Multifocal Iol ◽  
The Mean ◽  
Optical Phenomena ◽  
Presbyopia Correction

Aim. Evaluation of the visual and functional results of bilateral implantation of the diffractive trifocal intraocular lens (IOL), the incidence of adverse optical phenomena and the degree of patient satisfaction. Methods. A prospective, open-label study included 82 patients (164 eyes) with presbyopia who underwent cataract phacoemulsification (n = 128) or refractive lensectomy (n = 36) with bilateral implantation of a new multifocal IOL AT LISA tri 839MP. The mean age of the patients was 61.2 ± 11.8 (32-84) years. The period of observation of patients was from 6 to 36 (18.3 ± 3.9) months. Results. After 1 year of follow-up, the increase in UCNVA was observed from 0.19 ± 0.17 to 0.89 ± 0.21, UCIVA from 0.18 ± 0.20 to 0.78 ± 0.17, UCDVA from 0.26 ± 0, 23 to 0.9 ± 0.12 (p

Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study

2005 ◽  
Vol 107 (3) ◽  
pp. 187-190 ◽  
Author(s):  
José M. Ponseti ◽  
Jamal Azem ◽  
José M. Fort ◽  
Agustín Codina ◽  
J. Bruno Montoro ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
One Year

scholarly journals One-Year Open-Label Study of Entacapone in Patients with Advanced Parkinson Disease

2007 ◽  
Vol 3 (2) ◽  
pp. 82 ◽  
Author(s):  
Tae-Beom Ahn ◽  
Joo-Hyuk Im ◽  
Myoung Chong Lee ◽  
Jae Woo Kim ◽  
Won Yong Lee ◽  
...  
Keyword(s):  
Parkinson Disease ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
One Year
Sign in / Sign up

Export Citation Format

Share Document